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We examined cancer mortality at ages 13–29 years in England and Wales between 1981 and 2005, a total of 20026 deaths over
approximately 303 million person-years (mpy) at risk by sex, age group and time period. Overall, the mortality rate was 65.6 per mpy.
Malignant neoplasms of the central nervous system showed the highest rate (8.5), followed by myeloid and monocytic leukaemia
(6.6), lymphoid leukaemia (6.4), malignant bone tumours (5.4) and non-Hodgkin’s lymphoma (5.2). These groups together accounted
for almost 50% of all cancer deaths. The mortality rate for males (72.4) was 23% higher than for females (58.6) (P-value o0.0001).
Males showed significantly higher mortality rates than females in almost all diagnostic groups, in general, mortality increasing with age
(P-value o0.0001). There were significant decreases in mortality over time, the annual percentage change between 1981 and 2005
being minus 1.86 (95% confidence interval  2.09 to  1.62). Cancer groups with the highest mortality differed from those with the
highest incidence.
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One in four of all deaths in the United Kingdom is caused by
cancer (Coleman et al, 1999). Although the majority of these
deaths occur in the elderly, cancer represents the most common
cause of death at ages 13–29 years. Approximately 2500 teenagers
and young adults (TYAs) died from cancer in England and Wales
in the 4-year period 2002–2005. Little is known about the aetiology
of cancers in such young people, though; it is likely that it differs
from that in older adults (Birch, 2005, pp 13–31).
We carried out detailed analyses of mortality rates by cancer
group, sex, age and time period in persons aged 13–29 years in
England and Wales, to identify the highest mortalities and lowest
reductions in mortality over time; these, it is hoped, will assist with
targeting of clinical resources and service planning.
METHODS
Mortality data on neoplasms in England and Wales from 1981 to
2005 were provided by the Office for National Statistics, London
(ONS); those covered malignant neoplasms, benign tumours and
neoplasms of uncertain behaviour, in those aged 13–29 years. For
each observation, age at death, sex, and diagnosis coded according
to the International Classification of Diseases (ICD) were included.
Data on cases registered from 1981 to 2001, a period that spans
both the ICD Ninth Revision (ICD-9) (World Health Organization,
1977) and ICD Tenth Revision (ICD-10) (World Health Organiza-
tion, 1992) coding epochs at the ONS, were released by the English
Cancer Information System (Office for National Statistics, 2004)
along with the tabulation for the conversion from the earlier ICD-9
to ICD-10. Direct translation between ICD-9 and ICD-10 at the
4-digit level for all codes was not possible. We, therefore, used the
ICD-10 codes up to the third digit. For comparison purposes, we
also considered incidence data on all registered neoplasms
diagnosed in England from 1979 to 2003 inclusive, supplied by
the National Cancer Intelligence Centre, ONS, London (Office for
National Statistics, 2006b).
Mid-year estimates, by single year of age and sex, of the resident
population in England and Wales for the time period 1981–2005
were obtained, based on the national censuses (Office for National
Statistics, 2007). Number of deaths and population estimates were
tabulated by age, sex and time period. The age groups were 13–14,
15–19, 20–24 and 25–29 years. The time span was divided into
five quinquennia. Thirteen main diagnostic groups were defined as
shown in Table 1, three of which were further subclassified giving
14 groups in all and for each, mortality rates were calculated. The
European standard population was used for direct standardisation
of the rates (Quinn et al, 2005). Throughout this report rates are
given per million person-years (mpy).
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tested for by using a w
2 test statistic. Age and temporal trends was
tested for, by using a single degree of freedom w
2 statistic
(Armitage, 1955); the estimate of the percent change per year of
age (PCYA) was obtained by using a linear regression of the
natural logarithm of the rates; similarly, in the temporal analysis
the annual percent change (APC) was estimated by using a
weighted linear regression of the natural logarithm of the age-
adjusted rates where the weights were given by the inverse of the
estimated variance of the response variable (Kim et al, 2000).
Significance level was set at 5%.
The results of the separate stratified analyses were successively
assessed with Poisson additive models (Wood, 2006), including
main effects, interaction terms, and non-linear temporal trends
simultaneously. The statistical analyses were performed using Stata
v. 9.2 (StataCorp, 2005) and the software R (R Development Core
Team, 2006).
RESULTS
A total of 20026 deaths were registered over 25-year period in
people aged 13–29 years with ICD-10 codes C00-D48, of which 875
were from benign, uncertain or unknown behaviour tumours. There
were approximately 303 million person-years at risk. Overall, the
mortality rate was 65.6 per mpy (Table 2). Malignant tumours of the
central nervous system (CNS) showed the highest mortality rate
(8.5), followed by myeloid and monocytic leukaemia (MML) (6.6),
lymphoid leukaemia (LL) (6.4), malignant bone tumours (bone)
(5.4) and non-Hodgkin’s lymphoma (NHL) (5.2). These groups
together accounted for almost 50% of all deaths under study.
Overall, the mortality rate for males (72.4) was 23% higher than
for females (58.6), and significantly higher in all the specified
groups except breast and genitourinary (GU) organs, where
females had higher rates; there was no significant heterogeneity
by sex for liver cancer, melanoma, GU sites other than gonads and
cervix, thyroid and non-malignant neoplasms of the CNS. There
were large disproportions of rates between males and females
for cancers of the lip, oral cavity and pharynx, respiratory
organs, bone and lymphomas and leukaemias. In these groups,
the ratio of rates in males compared to females was between 1.5
and 2.2.
The mortality differed between age groups for all specified
diagnostic groups except thyroid and other endocrine glands
(Table 3). The rates for breast and cervical cancer increased by
50% for each additional year of age. Marked increases across age
groups were also observed for digestive organs (excluding liver),
melanoma of skin and testicular cancer, whereas for bone cancer
decreases on average by nearly 8% per year of age, the largest drop
among the diagnostic groups. Lymphomas and MML rates
increased rates with age, with the largest increases at ages 13–19
years. Mortality for LL peaked at age 15–19 years. For Hodgkin’s
lymphoma (HL), mortality for persons aged 25–29 years was 11
times higher than the rate for those aged 13–14 years.
When using the Poisson regression approach, few groups
showed a significant interaction between sex and age. For bone,
the relative risk in males compared to females increased with age,
from 0.8 (95% confidence interval, CI, 0.6–1.1) at 13–14 years to
2.1 (95% CI 1.6–2.8) at 25–29 years. For NHL, the relative risk
decreased by age, in males being three (95% CI 1.7–5.3) times
higher at 13–14 years and 1.7 (95% CI 1.4–2) times higher at 25–
29 years.
Table 1 Diagnostic groups based on the ICD-10 codes used for the analysis of the mortality data of persons aged 13–29 years in England and Wales
from 1981 to 2005
Description
Main group Subgroup ICD-10 codes
Lip, oral cavity and pharynx C00–C14
Digestive organs C15–C26
Colorectal C18, C19, C20
Liver C22
Other sites in GI tract C15–C17, C21, C23–C26
Respiratory and intra-thoracic organs C30–C39
Bone and articular cartilage C40–C41
Melanoma of skin C43
Mesothelial and soft tissue C45–C49
Breast C50
Genitourinary organs C51–C68
Cervix C53
Ovary C56
Testis C62
Other sites C51, C52, C54, C55, C57–C61, C63–C68
Eye, brain, and other parts of CNS C69–C72
Thyroid and other endocrine glands C73–C75
Malignant neoplasms of lymphoid,
haematopoietic, and related tissue
C81–C96
Lymphoid leukaemia C91
Myeloid and monocytic leukaemia C92, C93
Hodgkin’s lymphoma C81
Non-Hodgkin’s lymphoma C82, C83, C84, C85
Other and unspecified lympho-haematopoietic C88, C90, C94, C95, C96
Other malignant neoplasms C44, C76–C80, C97
Benign neoplasms and neoplasms
of uncertain behaviour
D10-D48
Eye, brain, and other parts of CNS D31, D32, D33, D42, D43
Other sites D10-D30, D34-D41, D44-D48
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on average each year (Table 4). Numbers decreasing from about
1000 per year in 1981–1985 to a little over 600 per year in 2001–
2005 period. Testicular cancer showed the largest APC ( 6.31),
followed by HL ( 5.12), cancer of respiratory and intra-thoracic
organs ( 4.26), and cervical cancer ( 4.07). Neither the total nor
the sex-specific mortality rates for bone showed a significant trend
over time. Further analyses revealed that the rates, after decreasing
in the first three time periods, increased in the last 10 years at age
20–24 years (APC 1.43, CI 0.16–2.72); this was also supported by
the Poisson regression.
Groups with the highest mortality (CNS, MML, LL, bone, NHL)
differed from those with the highest incidence (HL, testis,
melanoma, CNS, cervix) (Table 5). CNS, MML, LL, bone and soft
tissue were all in the top 10 for mortality and were between 3 and 8
rank places higher than for incidence. The ratio of incidence to
mortality varied from 16:1 for testis and 11:1 for thyroid cancer
to where the rates are similar, as for liver. The ratio for MML, LL,
and bone was below 2:1. Testicular and cervical cancer,
melanoma, and HL were among the top five groups with the
highest incidence between 1979 and 2003 but below the 5th
position for mortality between 1981 and 2005, with deaths
numbering much below that of new cases.
In 2002–2005, approximately 2500 TYAs in England died from
neoplasms, of which 2341 were coded as malignant, making cancer
the commonest disease-related cause of death at these ages,
accounting for approximately 12% of all deaths and exceeded only
by deaths from transport accidents, though at 13–14 years
neoplasmic deaths outnumbered deaths from any other cause
(Table 6). Deaths from all causes by sex and age group showed a
heterogeneous distribution.
Among the 875 deaths coded as being due to benign (275) or
uncertain and unknown behaviour (600) neoplasms, 166 involved
endocrine glands, 49 middle ear, respiratory and intrathoracic
organs, 57 mesothelial and soft tissue, 31 haemopoietic and 23 of
GU organs and 549 other sites.
DISCUSSION
This is the first study to present detailed analyses of cancer
mortality in TYAs in England and Wales and makes use of recent
national data over a 25-year period. The introduction of ICD-10 in
2001 had an impact on the analysis of trends in cancer mortality
(Brock et al, 2004). Comparability ratios provide a measure of the
effect of changes in coding practice that may vary by site and age.
Approximated estimates of variations in rates of TYA mortality
trends showed substantial robustness of the data to the introduc-
tion of the ICD-10 coding system. The results demonstrate that
cancer mortality in TYAs has decreased over time. Yet, cancer is
still the most common disease-related cause of death in this age
group. Moreover, the sites of most lethal cancers differ from those
at higher ages (Office for National Statistics, 2006a). Some of the
deaths due to benign neoplasms or those of uncertain behaviour
may have been miscoded or reported inaccurately. However, the
small proportion of deaths so assigned to ill-defined sites supports
the robustness of the data.
Major mortality reductions occurred for cancers of (i)
respiratory and intrathoracic organs, mainly bronchus and lung,
(ii) GU organs, cervical and testicular cancer in particular, and (iii)
HL; whereas cancers of digestive organs, soft tissue, and CNS
showed lower decreases in rates and less favourable incidence to
Table 2 Number of deaths (N) and mortality rates (R) per million person–years at risk by sex and diagnostic group at ages 13–29 years in England and
Wales, 1981–2005
Male Female Persons
P-value
Main group Subgroup NR N RNR Heter.
Lip, oral cavity and pharynx 194 1.3 98 0.6 292 1.0 o0.0001
Digestive organs 765 4.9 571 3.7 1336 4.3 o0.0001
Colorectal 300 1.9 206 1.4 506 1.6 o0.0001
Liver 164 1.1 148 1.0 312 1.0 0.4268
Other sites in GI tract 301 1.9 217 1.4 518 1.7 0.0003
Respiratory and intrathoracic organs 257 1.7 162 1.1 419 1.4 o0.0001
Bone and articular cartilage 993 6.5 632 4.3 1625 5.4 o0.0001
Melanoma of skin 420 2.7 364 2.4 784 2.5 0.0526
Mesothelial and soft tissue 620 4.0 462 3.1 1082 3.5 o0.0001
Breast 1 0.0 719 4.6 720 2.3 o0.0001
Genitourinary organs 783 5.1 1376 8.9 2159 7.0 o0.0001
Cervix — — 773 5.0 773 5.0 —
Ovary — — 410 2.7 410 2.7 —
Testis 621 4.0 — — 621 4.0 —
Other sites 162 1.0 193 1.3 355 1.2 0.0806
Malignant neoplasms of CNS 1531 10.0 1068 7.1 2599 8.5 o0.0001
Thyroid and other endocrine glands 150 1.0 139 0.9 289 1.0 0.6136
Malignant neoplasms of lymphoid,
haematopoietic and related tissue
4410 28.7 2610 17.3 7020 23.1 o0.0001
Lymphoid leukaemia 1308 8.6 620 4.2 1928 6.4 o0.0001
Myeloid and monocytic leukaemia 1154 7.5 844 5.6 1998 6.6 o0.0001
Hodgkin’s lymphoma 762 4.9 516 3.4 1278 4.2 o0.0001
Non-Hodgkin’s lymphoma 1037 6.7 548 3.6 1585 5.2 o0.0001
Other and unspecified lympho-haematopoietic 149 1.0 82 0.6 231 0.8 o0.0001
Other malignant neoplasms 522 3.4 304 2.0 826 2.7 o0.0001
Benign neoplasms and neoplasms
of uncertain behaviour
489 3.2 386 2.6 875 2.9 0.0011
Eye, brain, and other parts of CNS 204 1.3 184 1.2 388 1.3 0.3823
Other sites 285 1.9 202 1.4 487 1.6 0.0003
All groups 11135 72.4 8891 58.6 20026 65.6 o0.0001
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13–14 15–19 20–24 25–29
P-value
PCYA
a
Main group Subgroup NRNRNRNR Heter. Value (95% CI)
Lip, oral cavity and pharynx 19 0.6 68 0.8 88 1.0 117 1.3 0.0006 5.52* (2.82,8.30)
Digestive organs 26 0.8 147 1.7 358 4.0 805 8.7 o0.0001 18.71* (17.47,19.97)
Colorectal 8 0.2 46 0.5 131 1.4 321 3.5 o0.0001 21.97* (18.19,25.88)
Liver 14 0.4 66 0.8 99 1.1 133 1.4 o0.0001 8.03* (5.87,10.25)
Other sites in GI tract 4 0.1 35 0.4 128 1.4 351 3.8 o0.0001 29.03* (24.33,33.90)
Respiratory and intrathoracic organs 10 0.3 48 0.6 111 1.2 250 2.7 o0.0001 17.66* (14.82,20.57)
Bone and articular cartilage 199 6.0 673 7.8 503 5.6 250 2.7 o0.0001  7.63* ( 10.43, 4.75)
Melanoma of skin 7 0.2 60 0.7 239 2.6 478 5.2 o0.0001 27.63* (21.44,34.13)
Mesothelial and soft tissue 71 2.1 282 3.3 361 4.0 368 4.0 o0.0001 3.75* (1.63,5.91)
Breast 0 0.0 9 0.1 72 0.8 639 6.9 o0.0001 49.81* (44.42,55.42)
Genitourinary organs 32 1.0 186 2.2 562 6.2 1379 14.9 o0.0001 22.21* (20.42,24.02)
Cervix 0 0.0 6 0.1 123 2.7 644 13.9 o0.0001 54.12* (47.02,61.56)
Ovary 11 0.7 58 1.4 124 2.8 217 4.7 o0.0001 14.67* (11.83,17.59)
Testis 2 0.1 73 1.7 216 4.8 330 7.1 o0.0001 26.51* (17.88,35.77)
Other sites 19 0.6 49 0.6 99 1.1 188 2.0 o0.0001 11.85* (8.72,15.07)
Malignant neoplasms of CNS 260 7.8 570 6.6 721 8.0 1048 11.3 o0.0001 3.85* (2.03,5.71)
Thyroid and other endocrine glands 29 0.9 82 0.9 83 0.9 95 1.0 0.8513 0.91 ( 1.64,3.52)
Malignant neoplasms of lymphoid,
haematopoietic and related tissue
543 16.2 1864 21.6 2129 23.5 2484 26.8 o0.0001 3.13* (2.05,4.23)
Lymphoid leukaemia 261 7.8 768 8.9 536 5.9 363 3.9 o0.0001  6.36* ( 8.17, 4.52)
Myeloid and monocytic leukaemia 147 4.4 478 5.5 616 6.8 757 8.2 o0.0001 4.50* (3.75,5.27)
Hodgkin’s lymphoma 20 0.6 207 2.4 451 5.0 600 6.5 o0.0001 15.88* (11.04,20.94)
Non-Hodgkin’s lymphoma 78 2.3 340 3.9 466 5.2 701 7.6 o0.0001 7.97* (6.52,9.43)
Other and unspecified lympho-haematopoietic 37 1.1 71 0.8 60 0.7 63 0.7 0.0803  2.12 ( 6.45,2.41)
Other malignant neoplasms 27 0.8 135 1.6 218 2.4 446 4.8 o0.0001 13.80* (10.97,16.69)
Benign neoplasms and neoplasms of uncertain behaviour 89 2.7 199 2.3 250 2.8 337 3.6 o0.0001 3.36* (2.02,4.72)
Eye, brain, and other parts of CNS 42 1.3 78 0.9 105 1.2 163 1.8 o0.0001 4.58* (1.19,8.08)
Other sites 47 1.4 121 1.4 145 1.6 174 1.9 0.0526 2.41* (0.91,3.93)
All groups 1312 39.2 4323 50.0 5695 63.0 8696 93.8 o0.0001 6.53* (5.80,7.26)
aPercentage change per year of age. *Denotes significance at the 5% level.
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EpidemiologyTable 4 Number of deaths (N) and mortality rates (R) per million person–years at risk by time period and diagnostic group at ages 13–29 years in England and Wales, 1981–2005
1981–1985 1986–1990 1991–1995 1996–2000 2001–2005 P-value APC
a
Main group Subgroup NRNRNRNRNR Heter. Trend value (95% CI)
Lip, oral cavity and pharynx 63 1.0 69 1.0 53 0.9 57 1.0 50 0.9 0.7776 0.5251  0.54 ( 1.64,0.56)
Digestive organs 298 4.8 317 4.8 253 3.9 247 4.2 221 3.9 0.0226 0.0053  0.92* ( 1.82,0.00)
Colorectal 116 1.9 120 1.8 82 1.2 104 1.8 84 1.5 0.0330 0.1086  0.41 ( 1.87,1.06)
Liver 66 1.0 71 1.1 58 0.9 52 0.9 65 1.1 0.6814 0.9109  0.13 ( 1.86,1.63)
Other sites in GI tract 116 1.9 126 1.9 113 1.7 91 1.5 72 1.3 0.0466 0.0028  1.66* ( 3.05, 0.25)
Respiratory and intrathoracic organs 139 2.3 90 1.4 74 1.1 63 1.1 53 0.9 o0.0001 o0.0001  4.26* ( 5.56, 2.94)
Bone and articular cartilage 414 6.2 331 5.2 280 4.8 280 5.1 320 5.6 0.0104 0.1444  0.49 ( 1.31,0.34)
Melanoma of skin 167 2.7 165 2.4 183 2.8 134 2.3 135 2.4 0.3428 0.2319  0.64 ( 1.69,0.43)
Mesothelial and soft tissue 231 3.6 258 3.9 232 3.8 190 3.4 171 3.0 0.0648 0.0339  0.86 ( 1.76,0.05)
Breast 176 3.0 174 2.6 151 2.2 127 2.0 92 1.6 o0.0001 o0.0001  2.62* ( 3.48, 1.75)
Genitourinary organs 623 10.1 560 8.4 412 6.2 311 5.2 253 4.5 o0.0001 o0.0001  4.24* ( 4.90, 3.56)
Cervix 207 7.0 199 5.9 159 4.6 115 3.7 93 3.3 o0.0001 o0.0001  4.07* ( 5.20, 2.92)
Ovary 116 3.7 87 2.6 85 2.6 70 2.4 52 1.8 0.0003 o0.0001  2.80* ( 4.02, 1.57)
Testis 207 6.6 183 5.4 106 3.3 75 2.6 50 1.8 o0.0001 o0.0001  6.31* ( 7.48, 5.11)
Other sites 93 1.5 91 1.4 62 1.0 51 0.9 58 1.0 0.0039 0.0009  2.60* ( 4.10, 1.07)
Eye, brain, and other parts of CNS 559 8.8 609 9.4 534 8.7 435 7.6 462 8.1 0.0170 0.0141  0.74* ( 1.47, 0.01)
Thyroid and other endocrine glands 62 1.0 64 1.0 70 1.2 50 0.9 43 0.8 0.2553 0.2294  0.77 ( 3.11,1.62)
Lymphoid, haematopoietic and related tissue 1858 28.8 1636 25.1 1461 23.8 1106 19.7 959 16.9 o0.0001 o0.0001  2.57* ( 2.93, 2.22)
Lymphoid leukaemia 469 7.1 463 7.3 385 6.6 346 6.3 265 4.6 o0.0001 o0.0001  1.81* ( 2.62, 0.99)
Myeloid and monocytic leukaemia 555 8.6 463 7.1 387 6.3 312 5.5 281 4.9 o0.0001 o0.0001  2.70* ( 3.42, 1.97)
Hodgkin’s lymphoma 397 6.3 335 5.0 270 4.2 139 2.4 137 2.4 o0.0001 o0.0001  5.12* ( 6.07, 4.15)
Non-Hodgkin’s lymphoma 362 5.6 331 5.0 382 6.0 271 4.8 239 4.2 o0.0001 0.0008  1.20* ( 2.11, 0.28)
Other and unspecified 75 1.2 44 0.7 37 0.6 38 0.7 37 0.6 0.0029 0.0034  3.31* ( 5.26, 1.32)
Other malignant neoplasms 166 2.6 141 2.1 195 3.0 166 2.8 158 2.8 0.0189 0.1097 0.46 ( 0.81,1.75)
Benign and uncertain behaviour 235 3.7 145 2.2 172 2.9 181 3.2 142 2.5 o0.0001 0.0435  1.02 ( 2.35,0.32)
Eye, brain, and other parts of CNS 112 1.8 61 0.9 75 1.2 73 1.3 67 1.2 0.0012 0.0690  1.61 ( 3.50,0.32)
Other sites 123 1.9 84 1.3 97 1.6 108 1.9 75 1.3 0.0075 0.2782  0.38 ( 1.82,1.09)
All groups 4991 78.4 4559 69.5 4070 65.2 3347 58.5 3059 53.9 o0.0001 o0.0001  1.86* ( 2.09, 1.62)
aAnnual percentage change. *Denotes significance at the 5% level.
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ymortality ratios. There were no corresponding incidence falls of
these cancers in TYAs and in contrast some temporal increases
have been noted (Birch, 2005). The marked reductions in mortality
must therefore be due to well-documented improvements in
survival, particularly from testis cancer and HL (Coleman et al,
1999). Given our study period, it is likely that cervical screening
will have contributed to the reduction in cervix cancer mortality.
That from melanoma remained relatively constant over time, in
spite of an increase in incidence, and was higher in males. In
contrast, incidence was higher in females indicating that survival
for melanoma is higher in females and has increased over time.
Increased public and physician awareness of melanoma in young
people may have contributed to these changes.
Previous national studies of cancer mortality in England and
Wales presented data up to 1997 (Swerdlow et al, 2001) and 2003
(Quinn et al, 2001; Rowan et al, 2005) and included figures for
broad and variable age groups (e.g. 15–34, 20–44) depending on
cancer site. Furthermore, not all relevant cancer sites were
reported in detail for example bone, soft tissue, thyroid, HL,
MML, LL and liver (Quinn et al, 2001); bone, soft tissue, MML, LL
(Swerdlow et al, 2001), thereby preventing direct comparisons.
Levi et al (2003) reported mortality trends at 15–24 years in
Europe, including the United Kingdom but compared, 1965–1969
with 1995–1998, and only for selected diagnostic groups (bone,
soft tissue, testis, NHL, HL, and all leukaemias combined), again,
precluding direct comparison.
A recent study from the United States covering the period 1975–
2000 included some mortality at ages 15–29 years (Bleyer et al,
2006), but was primarily on incidence and survival. In general, the
trends were compatible with the present study though some
differences were apparent. Thus, decreases in mortality at 15–29
years were reported for melanoma, colorectal carcinoma and
testicular cancers; there were smaller reductions for CNS tumours
and breast cancer. For liver cancer there was an overall decrease,
but mortality increased in the more recent years, but time trends
for other groups were not reported. In the present study, up to year
Table 5 Ranking of selected diagnostic groups based on the number (N) of deaths from 1981 to 2005 and ranking based on the number of new cases
registered in England from 1979 to 2003 in persons at 13–29 years
Mortality Incidence
Group N %
a Rank N %
b Rank I:M ratio
c
Eye, brain, and other parts of CNS 2473 13.9 1 6003 8.2 4 2.4
Myeloid and monocytic leukaemia 1899 10.7 2 3095 4.2 8 1.6
Lymphoid leukaemia 1843 10.4 3 2663 3.7 11 1.4
Bone and articular cartilage 1538 8.7 4 2760 3.8 10 1.8
Non-Hodgkin’s lymphoma 1513 8.5 5 4873 6.7 6 3.2
Hodgkin’s lymphoma 1209 6.8 6 9778 13.4 1 8.1
Mesothelial and soft tissue 1019 5.7 7 2539 3.5 13 2.5
Melanoma of skin 731 4.1 8 6744 9.3 3 9.2
Cervix 713 4.0 9 5520 7.6 5 7.7
Breast 683 3.9 10 3874 5.3 7 5.7
Testis 590 3.3 11 9757 13.4 2 16.5
Other sites in GI tract 487 2.7 12 819 1.1 19 1.7
Colorectal 485 2.7 13 1511 2.1 16 3.1
Respiratory and intrathoracic organs 402 2.3 14 1051 1.4 18 2.6
Ovary 376 2.1 15 2417 3.3 14 6.4
Benign and uncertain behaviour - CNS 373 2.1 16 2627 3.6 12 7.0
Other sites in GU organs 338 1.9 17 1762 2.4 15 5.2
Liver 295 1.7 18 389 0.5 20 1.3
Lip, oral cavity, and pharynx 276 1.6 19 1254 1.7 17 4.5
Thyroid and other endocrine glands 272 1.5 20 3063 4.2 9 11.3
Other and unspecified lympho-haematopoietic 222 1.3 21 381 0.5 21 1.7
All groups 17737 100 72880 100 4.1
aPercentage of all deaths.
bPercentage of all new cases.
cIncidence to mortality ratio; number of new cases divided by number of deaths.
Table 6 Numbers (N) and sex ratios (M:F) by age group for the 10 leading causes of death and all deaths at ages 13–29 years in England and Wales,
2002–2005
13–14 15–19 20–24 25–29 13–29
Cause of death N M:F N M:F N M:F N M:F N M:F
Transport accidents 138 2.7 1441 3.7 1538 5.2 1011 5.2 4128 4.5
Neoplasms 187 1.4 595 1.2 722 1.3 964 1.0 2468 1.2
Intentional self-harm 15 0.9 331 3.1 864 4.3 1113 3.6 2323 3.7
Diseases of the circulatory system 52 1.4 277 1.6 392 1.5 643 2.0 1364 1.7
Mental and behavioural disorders 18 1.2 157 2.1 479 4.4 709 5.0 1363 4.1
Diseases of the nervous system 101 1.5 422 2.2 402 1.8 398 1.6 1323 1.8
Diseases of the respiratory system 55 1.4 133 1.3 192 1.1 222 1.6 602 1.3
Endocrine, nutritional, and metabolic diseases 36 1.8 134 0.8 208 1.3 193 1.1 571 1.1
Malformations, deformations, and abnormalities 54 1.2 157 1.5 165 1.4 168 1.0 544 1.3
Diseases of the digestive system 14 0.6 64 1.2 129 1.3 265 1.8 472 1.5
Other causes 227 1.5 1292 2.4 1965 2.9 2259 2.7 5743 2.6
All deaths 897 1.5 5003 2.2 7056 2.7 7945 2.4 20901 2.4
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but there was a steady decrease in breast cancer and mortality
from liver cancer was stable. These differences may, at least in part,
be due to differences in the ethnic mix in the United States,
England, and Wales.
The recent guidance on improving outcomes in children and
young people with cancer, published by the National Institute for
Health and Clinical Excellence (National Collaborating Centre for
Cancer, 2005) noted the lack of available comprehensive data on
cancers in TYAs. The present report provides this for mortality in
England and Wales. The results highlight diagnostic groups, which
present the greatest clinical challenges, including those in which the
ratio of incidence to mortality is low, indicating poor survival and
those groups with little or no reductions in mortality over time. The
four leading causes of cancer death, CNS tumours, MML, LL, and
bone cancers, all have low incidence to mortality ratios. Further-
more, over the 25-year study period, mortality in CNS and bone
tumours has decreased by less than 1%. These observations may
assist with resource allocation and the setting of clinical targets.
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